Living Cell Technologies Limited
CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY
ASX ANNOUNCEMENT
Successful second implant of NTCELL for Parkinson’s
18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City
Hospital in the clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease. LCT plans to complete
the patient treatment phase of the study this year.
The Phase I/IIa clinical trial is an open-label investigation of the safety and clinical effects of NTCELL in patients
who can no longer respond to current therapy. The trial is directed by Dr Barry Snow MBChB, FRACP, FRCPC, an
internationally recognised clinician and researcher in Parkinson’s disease who leads the Auckland Movement Disorders
Clinic at the Auckland District Health Board.
Dr Ken Taylor, CEO of LCT says, “A great deal of hard work, preclinical research and scientific endeavour has gone into
the discovery and development of NTCELL. Our innovative approach is the first to target regeneration of brain cells for
patients who are failing the current conventional treatment for Parkinson’s disease.”
– Ends –
For further information: www.lctglobal.com